阿里(09988.HK)午後股價由紀錄高位倒跌1.5% 傳螞蟻尚未通過上市聆訊
市傳阿里巴巴-SW(09988.HK)旗下螞蟻集團至今尚未通過上市聆訊,阿里股價扭轉上午股價曾升至293元上市新高強勢,午後倒跌曾低見283.8元,現造285.2元,倒跌1.5%,成交增至1,769萬股。不過,Alibaba(BABA US)於美國股價四連漲,昨晚續升近1.4%收300.54美元創紀錄高,盤後再升近0.7%報302.5美元。
《彭博通訊社》報道,阿里巴巴旗下螞蟻集團原訂上周通過上市聆訊,但至今仍未通過。若其上市進程一再延後,接近美國總統大選將增加不確定因素。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.